CYT-0851 + rituximab + bendamustine

CYT-0851 is a first-in-class, orally available small molecule inhibitor targeting RAD51-mediated DNA repair and monocarboxylate transporters (MCTs). By inhibiting homologous recombination (HR), it leads to the accumulation of unrepaired double-strand DNA breaks and subsequent tumor cell death. It also blocks lactate transport, resulting in glycolytic cancer cell death. CYT-0851 has demonstrated promising clinical activity as both monotherapy and in combination with chemotherapy backbones, including rituximab and bendamustine, particularly in relapsed/refractory B-cell malignancies such as non-Hodgkin lymphoma (NHL) and advanced solid tumors. The drug is being developed by Cyteir Therapeutics[1][2][5][8].